Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Herrington

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Neurology|December 8, 2011
Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysisWilliam G Herrington
Heart (British Cardiac Society)|July 16, 2017
Extreme ischaemic heart disease risk in people with type 1 diabetesWilliam G Herrington, Fiona Bragg
Annals of Internal Medicine|November 4, 2024
In adults with BMI ≥27 kg/m<sup>2</sup> and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA<sub>1c</sub> levelDoreen Zhu, William G Herrington
The New England Journal of Medicine|July 10, 2024
Diabetic Kidney Disease - Semaglutide Flows into the MainstreamWilliam G Herrington, Richard Haynes
Annals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, initial invasive therapy did not improve angina-related health statusWilliam G Herrington, Natalie Staplin
Annals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, adding an invasive strategy to MT did not improve outcomesWilliam G Herrington, Natalie Staplin
The Lancet. Diabetes & Endocrinology|April 3, 2017
Tightening our understanding of intensive glycaemic controlWilliam G Herrington, David Preiss
Annals of Internal Medicine|November 4, 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortalityDoreen Zhu, William G Herrington
Annals of Internal Medicine|December 1, 2025
In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 moIain Turnbull, William G Herrington,
BMJ (Clinical Research Ed.)|February 7, 2012
Kidney failure with a diagnostic chest radiographWilliam G Herrington, David A Lewis
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Neurology|December 8, 2011
Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysisWilliam G Herrington
Heart (British Cardiac Society)|July 16, 2017
Extreme ischaemic heart disease risk in people with type 1 diabetesWilliam G Herrington, Fiona Bragg
Annals of Internal Medicine|November 4, 2024
In adults with BMI ≥27 kg/m<sup>2</sup> and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA<sub>1c</sub> levelDoreen Zhu, William G Herrington
The New England Journal of Medicine|July 10, 2024
Diabetic Kidney Disease - Semaglutide Flows into the MainstreamWilliam G Herrington, Richard Haynes
Annals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, initial invasive therapy did not improve angina-related health statusWilliam G Herrington, Natalie Staplin
Annals of Internal Medicine|August 18, 2020
In patients with coronary disease and CKD, adding an invasive strategy to MT did not improve outcomesWilliam G Herrington, Natalie Staplin
The Lancet. Diabetes & Endocrinology|April 3, 2017
Tightening our understanding of intensive glycaemic controlWilliam G Herrington, David Preiss
Annals of Internal Medicine|November 4, 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortalityDoreen Zhu, William G Herrington
Annals of Internal Medicine|December 1, 2025
In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 moIain Turnbull, William G Herrington,
BMJ (Clinical Research Ed.)|February 7, 2012
Kidney failure with a diagnostic chest radiographWilliam G Herrington, David A Lewis
Pageof 13